Breaking News Instant updates and real-time market news.

JPM

JPMorgan

$113.87

-1.45 (-1.26%)

, JNJ

Johnson & Johnson

$134.67

0.38 (0.28%)

20:25
07/15/19
07/15
20:25
07/15/19
20:25

Notable companies reporting before tomorrow's open

Notable companies reporting before tomorrow's open, with earnings consensus, include JPMorgan (JPM), consensus $2.50... Johnson & Johnson (JNJ), consensus $2.43... Wells Fargo (WFC), consensus $1.15... Goldman Sachs (GS), consensus $5... Prologis (PLD), consensus 36c... First Republic Bank (FRC), consensus $1.27... Domino's Pizza (DPZ), consensus $2.02... Synovus Financial (SNV), consensus 99c... First Horizon National (FHN), consensus 37c.

JPM

JPMorgan

$113.87

-1.45 (-1.26%)

JNJ

Johnson & Johnson

$134.67

0.38 (0.28%)

WFC

Wells Fargo

$46.70

-0.65 (-1.37%)

GS

Goldman Sachs

$211.55

-2.4 (-1.12%)

PLD

Prologis

$79.94

-0.09 (-0.11%)

FRC

First Republic

$98.61

-2.02 (-2.01%)

DPZ

Domino's Pizza

$269.97

-12.26 (-4.34%)

SNV

Synovus

$34.35

-1.08 (-3.05%)

FHN

First Horizon

$14.80

-0.305 (-2.02%)

  • 15

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 29

    Jul

  • 30

    Jul

  • 06

    Aug

  • 27

    Aug

  • 28

    Aug

  • 06

    Sep

  • 09

    Sep

  • 16

    Sep

  • 23

    Sep

  • 12

    Oct

  • 13

    Nov

JPM JPMorgan
$113.87

-1.45 (-1.26%)

06/24/19
UBSW
06/24/19
NO CHANGE
UBSW
DFAST results encourgaing for Wells Fargo, says UBS
UBS analyst Saul Martinez said the DFAST results from the Federal Reserve, reported after the close on Friday, were most encouraging for "those who didn't fare as well last year," like Wells Fargo (WFC). He thinks Goldman Sachs (GS), Morgan Stanley (MS) and State Street (STT) look like they have room to reach his forecasted capital returns and also said lower stressed losses at Citi (C) and JPMorgan (JPM) could suggest that the current SCB proposal may not lead to materially higher minimum capital requirements, added Martinez. However, he thinks there could be some downside to his capital return estimates for Capital One (COF), which he notes have been above consensus.
03/25/19
JEFF
03/25/19
NO CHANGE
JEFF
Jefferies downgrades Financials to Underweight on 'shocking' Fed meeting
Jefferies analyst Steven DeSanctis is "very surprised" by last week's Federal Reserve's decision taking rate hikes completely off table in 2019. The "shocking" Fed meeting means lower rates for longer, which is not good for Financials, DeSanctis tells investors in a research note. A "lack of catalysts and weaker earnings growth" going forward for the entire sector, not just banks, means an Underweight rating on the space makes sense, says the analyst. As such, he downgraded his rating on the Financial sector to Underweight from Market Weight. Publicly traded companies in the space include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
03/19/19
KEYB
03/19/19
DOWNGRADE
KEYB
Sector Weight
Worldpay downgraded to Sector Weight after Fiserv deal at KeyBanc
As previously reported, KeyBanc analyst Josh Beck downgraded Worldpay (WP) to Sector Weight from Overweight after the company and FIS (FIS) announced a deal, quickly adding another mega-deal in the wake of Fiserv (FISV)-First Data (FDC) and Global Payments (GPN)-Heartland Payment Systems. The analyst thinks this transaction is likely to expand the M&A discussion around Global Payments, TSYS (TSS), EVO Payments (EVOP), and i3 Verticals (IIIV) and sees paths to accretion should management teams further endorse a scale strategy. Future processing competition could increase among Global Payments, TSYS, First Data, and JPMorgan (JPM), but it remains too early to gauge, he contends.
06/19/19
MSCO
06/19/19
NO CHANGE
MSCO
Visa, MasterCard disruption threat from Libra 'fairly low,' says Morgan Stanley
After Facebook (FB) unveiled its cryptocurrency Libra yesterday, Morgan Stanley analysts led by Brian Nowak highlighted six "key questions" they still have about the impact on Facebook, commerce and the overall global banking and payments system from the social media giant's offering. The team, as previously stated, believe that Instagram commerce could be a greater than $4B annual opportunity for Facebook and even larger over the long term across Instagram, Messenger, WhatsApp and the core app. However, they also think costs may rise as they believe Facebook is likely going to have to fund rewards to drive Libra adoption. Libra's real-time aspect largely already exists in the banking system, except for in real-time cross-border payments, which is a challenge that Facebook could address, though it won't be alone there as JPMorgan (JPM) is also working on its own s Interbank Information Network blockchain, the team noted. The team believes Libra's threat of disruption to Visa (V) and Mastercard (MA) is "fairly low" as the major networks have a significant scale advantage, low costs, mature fraud detection abilities and they are both also founding members and investors, Nowak and the analysts also noted.
JNJ Johnson & Johnson
$134.67

0.38 (0.28%)

07/12/19
RAJA
07/12/19
NO CHANGE
RAJA
Outperform
DOJ investigation of J&J 'not new news,' says Raymond James
Raymond James analyst Jayson Bedford said that "technically" it is not "new news" that the DOJ is investigating Johnson & Johnson's communications around the alleged cancer risks of its talcum powder products as J&J previously disclosed an inquiry in its latest 10-Q filing. He notes J&J has responded to a Bloomberg article on the investigation by stating that there have been no new developments, though this risk was "clearly" underappreciated by investors. Though Bedford still thinks J&J has a strong case, today's reaction is an indication that the talc issue will remain "top-of-mind" and a headline risk, he added. Bedford has an Outperform rating on Johnson & Johnson shares.
07/11/19
JEFF
07/11/19
NO CHANGE
Target $40
JEFF
Buy
Australia implants decision a 'big positive' for Establishment, says Jefferies
After Australia's Therapeutic Goods Administration proposed to cancel or suspend use of textured breast implants, concluding that these devices are associated with a higher rate of anaplastic large cell lymphoma, or ALCL, Jefferies analyst Raj Denhoy called the decision a "big positive" for Establishment Labs (ESTA). The decision is still in the proposal stage, but Establishment is the only manufacturer with products approved in Australia that is not on the list, which proposes to ban implants from Allergan (AGN), J&J's (JNJ) Mentor and other manufacturers, according to Denhoy. He keeps a Buy rating and $40 price target on shares of Establishment Labs.
07/12/19
FBCO
07/12/19
INITIATION
Target $156
FBCO
Outperform
Johnson & Johnson assumed with an Outperform at Credit Suisse
Credit Suisse analyst Matt Miksic assumed coverage of Johnson & Johnson with an Outperform rating and $156 price target. In a research note to investors, Miksic cites key drivers to the rating, including continued growth in Immunology, driven by Stelera and Tremfya, sustainable growth in Oncology driven by Imbruvica, Darzelex and Erleada, an "attractive" pipeline of filings in the 2019-2023 timeframe with greater than$1B potential each, and "stable" growth and cash flows in Medical Devices and Consumer.
07/12/19
WELS
07/12/19
NO CHANGE
Target $29
WELS
Outperform
Australia implant ban 'excellent news' for Establishment Labs, says Wells Fargo
Wells Fargo analyst David Maris believes Australia's proposal to ban, suspend or impose strict restrictions on a number of textured implants from Allergan (AGN), Johnson & Johnson (JNJ) and other smaller manufacturers is "excellent news" for Establishment Labs Holdings (ESTA). The move by Australia's regulatory body Therapeutic Goods Administration will help solidify Establishment's reputation for safety as the company's Motiva brand is the only listed company without any restricted brands, Maris tells investors in a research note. Further, Australia is a highly regulated and developed market, so the ban could help shift market share in other geographies outside of the county as well, contends the analyst. Maris reiterates an Outperform rating on Establishment Labs with a $29 priced target. The stock closed yesterday up $1.54 to $22.44.
WFC Wells Fargo
$46.70

-0.65 (-1.37%)

07/10/19
WOLF
07/10/19
DOWNGRADE
WOLF
Underperform
Wells Fargo downgraded to Underperform from Peer Perform at Wolfe Research
07/12/19
SBSH
07/12/19
DOWNGRADE
SBSH
Neutral
Wells Fargo downgraded to Neutral from Buy at Citi
Citi analyst Keith Horowitz downgraded Wells Fargo to Neutral from Buy.
07/12/19
SBSH
07/12/19
NO CHANGE
SBSH
Morgan Stanley upgrade, Wells downgrade among Citi's bank changes
Citi analyst Keith Horowitz made seven rating changes in the U.S. Banks space after updating his estimates and target prices for a new base case rate forecast that more closely reflects the forward curve. This includes two interest rate cuts in 2019 and 2020. The analyst's terminal yield curve assumptions to Fed Funds is 1.75%. The lower rate assumptions led him to lower his normal return on tangible equity estimates ~100 basis points on average. Following these changes, Horowitz upgraded Morgan Stanley (MS) to Buy from Neutral), downgraded Comerica (CMA), Northern Trust (NTRS), and M&T Bank (MTB) to Sell from Neutral, and downgraded Wells Fargo (WFC), Citizens Financial (CFG), and Fifth Third (FITB) to Neutral from Buy.
07/12/19
07/12/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wells Fargo (WFC) downgraded to Neutral from Buy at Citi. 2. Rexnord (RXN) was downgraded to Underperform from Buy at BofA/Merrill while Parker-Hannifin (PH) was downgraded to Neutral from Buy. 3. Instructure (INST) downgraded to Market Perform from Outperform at Raymond James with analyst Brian Peterson saying his rating change "in no way reflects any incremental concerns about the company's strategic direction," but is entirely about his more cautious view on 2020 growth projections. 4. MSC Industrial (MSM) downgraded to Neutral from Buy at Northcoast with analyst Tom Hayes citing the company's report of weaker than expected organic sales growth and margin headwinds in Q3. 5. Charles Schwab (SCHW) was downgraded to Neutral from Buy at BofA/Merrill and to Market Perform from Outperform at Keefe Bruyette. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GS Goldman Sachs
$211.55

-2.4 (-1.12%)

06/20/19
ODEN
06/20/19
UPGRADE
ODEN
Buy
Goldman Sachs upgraded to Buy from Hold at Odeon Capital
Odeon Capital analyst Dick Bove upgraded Goldman Sachs to Buy from Hold.
06/20/19
06/20/19
UPGRADE

Buy
Odeon Capital says Goldman Sachs 'exciting again,' ups rating to Buy
As previously reported, Odeon Capital analyst Dick Bove upgraded Goldman Sachs to Buy from Hold saying that while the 2019 earnings estimates for the company had been falling consistently in the past 6 months, the projections are now starting to rise due to the bank's "strong" showing in investment banking and the impact that rising asset values may be having on the asset management business. Bove believes there is more to Goldman "than a strong second quarter," as it experiments with a series of new business thrusts. The company has the intellectual and financial capital to make many of these thrusts successful, he contends, adding that Goldman is "exciting again and it is becoming a compelling investment."
04/17/19
ODEN
04/17/19
UPGRADE
ODEN
Hold
Goldman Sachs upgraded to Hold from Sell at Odeon Capital
Odeon Capital analyst Dick Bove upgraded Goldman Sachs to Hold from Sell following details on the company's plan to "resurrect its fortunes." Bove said Goldman has the intellectual and financial capital to make it work, but it will take years to implement.
PLD Prologis
$79.94

-0.09 (-0.11%)

05/20/19
EVER
05/20/19
DOWNGRADE
EVER
In Line
Prologis downgraded to In Line from Outperform at Evercore ISI
05/20/19
05/20/19
DOWNGRADE
Target $78

In Line
Prologis downgraded to In Line on valuation at Evercore ISI
As previously reported, Evercore ISI analyst Steve Sakwa downgraded Prologis to In Line from Outperform given its sharp gains year to date and outperformance versus the REIT index. While the analyst is still positive on industrial fundamentals and believes the operational setup is strong over the next 12-24 months, he thinks much of this good news is priced into the stock and the risk/reward seems more balanced. Sakwa also raised his price target on the shares to $78 from $75.
05/20/19
EVER
05/20/19
UPGRADE
Target $100
EVER
In Line
Life Storage upgraded to In Line from Underperform at Evercore ISI
Evercore ISI analyst Steve Sakwa this morning upgraded Life Storage (LSI) to In Line from Underperform with an unchanged price target of $100. The stock year-to-date has underperformed peers even though the company, on an operational basis, performed relatively in line during Q1, Sakwa tells investors in a research note. The analyst, who believes it is too early to know how the peak leasing season will turn out, cites valuation for his upgrade of Life Storage to In Line. Sakwa this morning also downgraded Prologis (PLD) to In Line from Outperform.
05/15/19
GSCO
05/15/19
INITIATION
Target $87
GSCO
Conviction Buy
Prologis initiated with a Conviction Buy at Goldman Sachs
Goldman Sachs analysts led by Caitlin Burrows initiated coverage of five Industrial REITs with a favorable outlook, citing the view that demand will be driven by secular growth in e-commerce and cyclical factors and will remain strong. Burrows and the team started Prologis with a Buy rating and placed the stock on the Americas Conviction List, citing the strong SS NOI growth that is being driven by its strategy of prioritizing rate growth. They set a price target of $87 on Prologis shares.
FRC First Republic
$98.61

-2.02 (-2.01%)

03/15/19
BMOC
03/15/19
NO CHANGE
Target $111
BMOC
Market Perform
First Republic price target raised to $111 from $95 at BMO Capital
BMO Capital analyst Lana Chan raised her price target on First Republic to $111 and also raised her FY19 EPS view to $5.30 from $5.25 after meeting with its management. The analyst says the discussions highlighted the management's "positive outlook for client growth" in loans, deposits, and wealth management. Chan is keeping her Market Perform rating on the shares however, stating that the valuation premium on the stock relative to its peers has widened even further after its recent addition to the S&P500 index.
01/16/19
WELS
01/16/19
NO CHANGE
Target $110
WELS
Outperform
First Republic price target raised to $110 from $100 at Wells Fargo
Wells Fargo analyst Jared Shaw raised his price target for First Republic to $110 from $100 after the bank posted a "strong quarter" marked by record loan production and a better net interest margin. As one of the biggest consensus shorts heading into earnings, the strong balance sheet performance and better NIM result resulted in a 10% rebound in shares, he notes. Shaw continues to view First Republic as one of the best positioned banks, as it remains one of his top picks for 2019. He reiterates an Outperform rating on the shares.
06/14/19
FBCO
06/14/19
INITIATION
Target $5
FBCO
Neutral
First Republic initiated with a Neutral at Credit Suisse
Credit Suisse initiated First Republic with a Neutral and $105 price target.
03/01/19
ATLE
03/01/19
DOWNGRADE
ATLE
Neutral
First Republic downgraded to Neutral from Overweight at Atlantic Equities
DPZ Domino's Pizza
$269.97

-12.26 (-4.34%)

07/01/19
WELS
07/01/19
NO CHANGE
Target $267
WELS
Market Perform
Domino's Pizza price target raised to $267 from $257 at Wells Fargo
Wells Fargo analyst Jon Tower raised his price target for Domino's Pizza to $267 from $257, while reiterating a Market Perform rating on the shares. The analyst continues to believe the company has the best customer proposition within quick-service pizza, but thinks the proliferation of 3rd-party delivery will continue to weigh on delivery incumbents.
07/10/19
OTRG
07/10/19
DOWNGRADE
OTRG
Mixed
Domino's Pizza downgraded to Mixed from Positive at OTR Global
OTR Global downgraded Domino's Pizza to Mixed from Positive following checks that indicate weaker sales impacted by heavy coupon use and lack of menu innovation.
07/12/19
MAXM
07/12/19
NO CHANGE
Target $315
MAXM
Buy
Domino's Pizza EPS growth to accelerate in 2020, says Maxim
Maxim analyst Stephen Anderson kept his Buy rating and $315 price target on Domino's Pizza (DPZ) ahead of its Q2 results next week. The analyst expects the management to address its "fortressing" strategy that will allow the company to pick up market share given the ongoing troubles at Papa John's (PZZA). Anderson lowers his FY19 EPS outlook to $9.74 from $9.82 but believes that Domino's Pizza valuation is "attractive" at 10% below the August 2018 high. In FY20, the analyst expects the company's earnings to accelerate to $11.71.
07/11/19
MSCO
07/11/19
NO CHANGE
Target $305
MSCO
Overweight
Domino's reasonably insulated from 3rd party delivery risk, says Morgan Stanley
Morgan Stanley analyst John Glass said he is not dismissive of the sales risk posed to Domino's Pizza (DPZ) by third-party food delivery aggregators, but his county-by-county analysis of its U.S. stores overlapped against markets where third party delivery is or is expected to be most concentrated leads him to believe that the risk has a "reasonable boundary" of a 1%-2% impact on same-store sales. Using the same data, he concluded that Domino's still has an opportunity to grow its current U.S. store base of about 5,900 to at least 8,000-9,000 units over time, said Glass, who keeps an Overweight rating on Domino's shares with a $305 price target. Publicly traded companies that operate third-party food delivery services include GrubHub (GRUB) and Uber (UBER).
SNV Synovus
$34.35

-1.08 (-3.05%)

03/12/19
BOFA
03/12/19
NO CHANGE
BOFA
Dropbox, Synovus added to US 1 List at BofA/Merrill
04/04/19
RAJA
04/04/19
UPGRADE
RAJA
Strong Buy
Synovus upgraded to Strong Buy from Outperform at Raymond James
04/04/19
04/04/19
UPGRADE
Target $44

Strong Buy
Synovus upgraded to Strong Buy at Raymond James
As previously reported, Raymond James analyst David Lon upgraded Synovus (SNV) to Strong Buy from Outperform, with a $44 price target. The analyst cited the recent pullback in the stock and what he sees as an outsized opportunity for market share gain stemming from the recently announced BB&T (BBT)-SunTrust (STI) mega merger.
07/12/19
RBCM
07/12/19
INITIATION
Target $42
RBCM
Outperform
Synovus initiated with an Outperform at RBC Capital
RBC Capital analyst Steven Duong initiated Synovus with an Outperform rating and a price target of $42, saying the company's current financial performance and expected growth from its FCB Financial acquisition warrants a higher valuation. The analyst believes that the FCB deal deepens Synovus' presence in the "fast growing" Florida market, with the transition going smoothly and ahead of schedule. Duong also contends that the company's balance sheet has been de-risked with a more balanced loan portfolio since the financial crisis and expects its positive operating leverage trends to continue.
FHN First Horizon
$14.80

-0.305 (-2.02%)

04/04/19
GSCO
04/04/19
DOWNGRADE
Target $84
GSCO
Neutral
Goldman downgrades Comerica to Neutral from Buy as rate hikes wane
Goldman Sachs analyst Ryan Nash downgraded Comerica (CMA) to Neutral from Buy and lowered his price target for the shares to $84 from $89. While loan growth has begun to improve from the lows, a lack of additional interest rate hikes, along with more exposure to consumer deposits continuing to re-price higher, likely means that the company's margins will begin to compress beyond Q1, Nash tells investors in a research note. He believes this will "pressure" consensus estimates. In the Regional Banks space, the analyst is most upbeat on Signature Bank (SBNY), Citizens Financial (CFG) and Cadence Bancorp (CADE) into Q1. He's less optimistic on First Horizon (FHN) and Huntington Bancshares (HBAN).
04/08/19
SPHN
04/08/19
NO CHANGE
SPHN
Franklin Financial SNC notice likely refers to Nobilis Health, says Stephens
After Franklin Financial Network (FSB) disclosed that the administrative agent for a shared national credit, or "SNC," in which the company is one of several lenders issued a notice of default and reservation of rights to the borrower, Stephens analyst Tyler Stafford said he believes the SNC relationship is to Nobilis Health (HLTH). Based on prior filings, Stafford believes LegacyTexas Financial (LTXB), BOK Financial (BOKF) and First Horizon (FHN) may also have exposure to Nobilis, but he cannot be sure of their current exposures.
07/03/19
PIPR
07/03/19
INITIATION
Target $18
PIPR
Overweight
First Horizon assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Brett Rabatin assumed coverage of First Horizon National with an Overweight rating and $18 price target. The analyst sees less estimate risk for the company than many of its peers and he finds the stock's "slight discount from a valuation perspective attractive."
04/01/19
JEFF
04/01/19
NO CHANGE
JEFF
Jefferies upgrades Fifth Third, Wintrust to Buy, downgrades First Horizon
Jefferies analyst Ken Usdin upgraded both Fifth Third (FITB) and Wintrust Financial (WTFC) to Buy from Hold while downgrading First Horizon National (FHN) to Hold from Buy. Banks head into Q1 earnings season with a "complicated, but more attractive, set-up," Usdin tells investors in a research note. He believes negative earnings revisions based on the flatter curve will be "offset somewhat" by strong credit metrics. The analyst upgraded Fifth Third and raised his price target for the shares to $30 from $29 on earnings upside potential post the MB Financial deal close. Usdin upgraded Wintrust while lowering his price target for the shares to $77 from $78. He sees an attractive entry point following the recent underperformance. Usdin downgraded First Horizon and lowered his price target for the shares to $14 from $16.50 as he sees "meaningful" earnings revision risk.

TODAY'S FREE FLY STORIES

DB

Deutsche Bank

$6.98

-0.19 (-2.65%)

, COF

Capital One

$83.06

-2.68 (-3.13%)

17:57
08/23/19
08/23
17:57
08/23/19
17:57
Periodicals
Deutsche Bank, Capital One won't say if they have Trump's tax returns, NYP says »

Deutsche Bank (DB) and…

DB

Deutsche Bank

$6.98

-0.19 (-2.65%)

COF

Capital One

$83.06

-2.68 (-3.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

MXIM

Maxim Integrated

$52.14

-2.42 (-4.44%)

17:53
08/23/19
08/23
17:53
08/23/19
17:53
Hot Stocks
Maxim Integrated's Jain sells 12,683 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

GLD

SPDR Gold Shares

$144.15

2.77 (1.96%)

17:42
08/23/19
08/23
17:42
08/23/19
17:42
Hot Stocks
SPDR Gold Shares holdings rise to 859.83MT to 854.84MT »

This is the fourth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUMN

Golden Minerals

$0.27

0.0159 (6.38%)

17:33
08/23/19
08/23
17:33
08/23/19
17:33
Hot Stocks
Golden Minerals receives noncompliance notice from NYSE »

Golden Minerals announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMPI

DelMar Pharmaceuticals

$0.77

0.0047 (0.61%)

17:25
08/23/19
08/23
17:25
08/23/19
17:25
Hot Stocks
Intracoastal Capital reports 9.99% passive stake in DelMar Pharmaceuticals »

Intracoastal Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$180.58

-6.44 (-3.44%)

17:22
08/23/19
08/23
17:22
08/23/19
17:22
Hot Stocks
Raytheon awarded $534M Army contract »

Raytheon was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHAL

Amerco

$339.43

-2.97 (-0.87%)

17:21
08/23/19
08/23
17:21
08/23/19
17:21
Hot Stocks
Amerco announces special cash dividend of 50c per share »

The dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTLA

Intellia Therapeutics

$15.77

-1.08 (-6.41%)

17:20
08/23/19
08/23
17:20
08/23/19
17:20
Syndicate
Breaking Syndicate news story on Intellia Therapeutics »

Intellia Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$183.42

-4.19 (-2.23%)

17:19
08/23/19
08/23
17:19
08/23/19
17:19
Hot Stocks
General Dynamics awarded $1.08B Navy contract modification »

General Dynamics has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVLN

Novelion Therapeutics

$0.66

-0.0523 (-7.37%)

17:17
08/23/19
08/23
17:17
08/23/19
17:17
Hot Stocks
Stonepine Capital reports 6.1% passive stake in Novelion Therapeutics »

Stonepine Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$376.85

-8.91 (-2.31%)

17:14
08/23/19
08/23
17:14
08/23/19
17:14
Hot Stocks
Lockheed Martin awarded $2.43B Navy contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCS

OncoSec

$1.84

-0.03 (-1.60%)

17:14
08/23/19
08/23
17:14
08/23/19
17:14
Syndicate
Breaking Syndicate news story on OncoSec »

OncoSec files $50M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNXP

Tonix Pharmaceuticals

$0.42

-0.0249 (-5.60%)

17:09
08/23/19
08/23
17:09
08/23/19
17:09
Syndicate
Breaking Syndicate news story on Tonix Pharmaceuticals »

Tonix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

17:08
08/23/19
08/23
17:08
08/23/19
17:08
General News
Trump to raises tariff rates on Chinese goods, CNBC says »

U.S. President Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATIS

Attis Industries

$1.03

-0.08 (-7.21%)

17:06
08/23/19
08/23
17:06
08/23/19
17:06
Hot Stocks
Attis Industries provides update on status of Nasdaq listing »

Attis Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVEO

Civeo

$1.32

-0.07 (-5.04%)

17:04
08/23/19
08/23
17:04
08/23/19
17:04
Syndicate
Breaking Syndicate news story on Civeo »

Civeo files $300M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGO

Assured Guaranty

$42.56

-1.09 (-2.50%)

16:58
08/23/19
08/23
16:58
08/23/19
16:58
Hot Stocks
Assured Guaranty CEO sells 30,300 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMED

Ra Medical Systems

$1.87

-0.055 (-2.86%)

16:50
08/23/19
08/23
16:50
08/23/19
16:50
Hot Stocks
Ra Medical Systems discloses NYSE notice related to 10-Q filing delay »

Ra Medical Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBA

Pembina Pipeline

$35.73

-0.81 (-2.22%)

16:47
08/23/19
08/23
16:47
08/23/19
16:47
Syndicate
Breaking Syndicate news story on Pembina Pipeline »

Pembina Pipeline files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

APEN

Apollo Endosurgery

$3.50

(0.00%)

16:44
08/23/19
08/23
16:44
08/23/19
16:44
Syndicate
Breaking Syndicate news story on Apollo Endosurgery »

Apollo Endosurgery files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:40
08/23/19
08/23
16:40
08/23/19
16:40
General news
Fed's Clarida said the global economy has worsened »

Fed's Clarida said…

LQDA

Liquidia Technologies

$5.23

-0.38 (-6.77%)

16:35
08/23/19
08/23
16:35
08/23/19
16:35
Syndicate
Breaking Syndicate news story on Liquidia Technologies »

Liquidia Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$175.24

-4.91 (-2.73%)

16:32
08/23/19
08/23
16:32
08/23/19
16:32
Hot Stocks
Visa CFO Prabhu sells over 25,000 class A common shares »

Visa vice chairman and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 27

    Oct

QCOM

Qualcomm

$73.57

-3.55 (-4.60%)

16:31
08/23/19
08/23
16:31
08/23/19
16:31
Hot Stocks
Qualcomm CFO Dave Wise to retire, Akash Palkhiwala named interim CFO »

Qualcomm announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 06

    Nov

ANFI

Amira Nature Foods

$0.58

-0.0144 (-2.44%)

16:30
08/23/19
08/23
16:30
08/23/19
16:30
Hot Stocks
Amira Nature Foods receives NYSE notice over late Form 20-F filing »

Amira Nature Food…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.